Inflarx (IFRX) Stock Rating Lowered by Zacks Investment Research

Share on StockTwits

Zacks Investment Research downgraded shares of Inflarx (NASDAQ:IFRX) from a buy rating to a hold rating in a research report report published on Thursday morning, Zacks.com reports.

According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “

A number of other research analysts have also weighed in on the stock. Robert W. Baird initiated coverage on shares of Inflarx in a research note on Monday, January 28th. They issued an outperform rating and a $62.00 target price on the stock. ValuEngine raised shares of Inflarx from a hold rating to a buy rating in a research note on Thursday, February 28th. JPMorgan Chase & Co. raised their target price on shares of Inflarx from $42.00 to $65.00 and gave the stock a top pick rating in a research note on Tuesday, February 5th. Finally, Guggenheim initiated coverage on shares of Inflarx in a research note on Friday, February 22nd. They issued a buy rating and a $65.00 target price on the stock. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $53.11.

IFRX opened at $50.56 on Thursday. Inflarx has a 1-year low of $20.31 and a 1-year high of $52.00. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -36.11 and a beta of -0.84.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IFRX. Bank of New York Mellon Corp purchased a new stake in shares of Inflarx during the 3rd quarter valued at approximately $277,000. Jane Street Group LLC purchased a new stake in shares of Inflarx during the 3rd quarter valued at approximately $278,000. JPMorgan Chase & Co. raised its position in shares of Inflarx by 29.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,700 shares of the company’s stock valued at $367,000 after buying an additional 2,420 shares during the period. Paloma Partners Management Co purchased a new stake in shares of Inflarx during the 4th quarter valued at approximately $526,000. Finally, Bank of America Corp DE purchased a new stake in shares of Inflarx during the 4th quarter valued at approximately $657,000. 51.01% of the stock is currently owned by institutional investors and hedge funds.

Inflarx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.

Featured Article: Why do companies issue convertible shares?

Get a free copy of the Zacks research report on Inflarx (IFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Inflarx (NASDAQ:IFRX)

Receive News & Ratings for Inflarx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inflarx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Guaranty Federal Bancshares, Inc.  Given Average Recommendation of “Buy” by Brokerages
Guaranty Federal Bancshares, Inc. Given Average Recommendation of “Buy” by Brokerages
Central Valley Community Bancorp  Expected to Announce Earnings of $0.40 Per Share
Central Valley Community Bancorp Expected to Announce Earnings of $0.40 Per Share
-$1.20 EPS Expected for Catalyst Biosciences Inc  This Quarter
-$1.20 EPS Expected for Catalyst Biosciences Inc This Quarter
Brokerages Set $48.00 Target Price for Lydall, Inc.
Brokerages Set $48.00 Target Price for Lydall, Inc.
First Republic Bank  Earns “Outperform” Rating from Wedbush
First Republic Bank Earns “Outperform” Rating from Wedbush
Littelfuse  Cut to Sell at Zacks Investment Research
Littelfuse Cut to Sell at Zacks Investment Research


 
© 2006-2019 Zolmax.